Revefenacin: Difference between revisions
Jump to navigation
Jump to search
| Line 39: | Line 39: | ||
*Revefenacin proved to have long duration of action and low systemic exposure (doesn't affect the whole body) for patients struggling with Chronic Obstructive Pulmonary Disease or COPD | *Revefenacin proved to have long duration of action and low systemic exposure (doesn't affect the whole body) for patients struggling with Chronic Obstructive Pulmonary Disease or COPD | ||
*88 mcg of this drug can result in constructive bronchodilation (to helps patients breathe better) | *88 mcg of this drug can result in constructive bronchodilation (to helps patients breathe better) | ||
Pharmacology trials: | |||
*Evaluted human recombitance mAChRs (muscarinic cholinergic receptor) by testing it on airway tissues from rats, guinea pigs, and humans | |||
**Revefenacin proved high affinity for the human tissue and competed against those five human recombinant mAChRs | |||
**This drug attacked "mAChRs mediated contractile responses" | |||
**This shows that revefenacin produces long-lasting attacking effects on this tissue from rats, guinea pigs, and humans | |||
Conclusion: | |||
*Revefenacin has the potential to be a daily dose broncholdilator for patients struggling from COPD | |||
==How is it supplied== | ==How is it supplied== | ||
Revision as of 04:02, 8 October 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Uma Maveli[2]
Overview
Adult Indications and Dosage
- The agreed dosage is 175 micrograms per day
- Taken via a standard jet nebulizer (turns liquid medication into mist) connected to an air compressor
- Makes it easy for patients with pulmonary problems
Pediatric Indications and Dosage
Contradictions
Warnings
Adverse Reactions
Side Effects
- Headache
- Cough
- Problems regarding the upper respiratory system
- Back Pain
Drug Interactions
Use in Specific Populations
IV Compatibility
- Intravenous solution in healthy volunteers
- Volume of distribution was 218 L
- Intravenous solution radioactivity:
- 54% came out as solid waste
- 27% came out as liquid waste
Pharmacology
See Clinical Studies
Clinical Studies
Trials:
- Revefenacin proved to have long duration of action and low systemic exposure (doesn't affect the whole body) for patients struggling with Chronic Obstructive Pulmonary Disease or COPD
- 88 mcg of this drug can result in constructive bronchodilation (to helps patients breathe better)
Pharmacology trials:
- Evaluted human recombitance mAChRs (muscarinic cholinergic receptor) by testing it on airway tissues from rats, guinea pigs, and humans
- Revefenacin proved high affinity for the human tissue and competed against those five human recombinant mAChRs
- This drug attacked "mAChRs mediated contractile responses"
- This shows that revefenacin produces long-lasting attacking effects on this tissue from rats, guinea pigs, and humans
Conclusion:
- Revefenacin has the potential to be a daily dose broncholdilator for patients struggling from COPD
How is it supplied
- Given to patients via jet nebulizer
Patient Counseling Information
Precautions with Alcohol
Brand Names
- Yupelri